Trade ABUS anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Arbutus Biopharma Corporation (ABUS) is trading at US$5.15, up 0.59% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$1.03B. Over the past 52 weeks, ABUS has traded between US$3.50 and US$5.45. On Syfe you can trade ABUS with $0 commission and add it to your watchlist.
| Previous close | US$5.12 |
|---|---|
| Market cap | US$1.03B |
| P/E ratio | 28.87 |
| 52-week range | US$3.50 – US$5.45 |
| Volume | 5.2M |
| Exchange | US |
Add to Watchlist
Set Price Alert
Arbutus Biopharma Corporation
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Year: 2007
Arbutus Biopharma Corporation (ABUS) stock is trading at US$5.15, +0.59% from the previous close of US$5.12.
The market cap for Arbutus Biopharma Corporation (ABUS) stock is approximately US$1.03B.
The price-to-earnings ratio for Arbutus Biopharma Corporation (ABUS) is 28.87, based on the latest reported earnings.
The 52-week high for Arbutus Biopharma Corporation (ABUS) stock is US$5.45.
The 52-week low for Arbutus Biopharma Corporation (ABUS) stock is US$3.50.
Arbutus Biopharma Corporation (ABUS) does not currently pay a dividend.
Stay on top of ABUS
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
